AshleySloaneMargolMDMS

Pediatric Hematology & Oncology • Hollywood, CA

Pediatric Neuro-Oncology

Director, Brain Tumor Center Director, Neuro-Oncology Program Director, Neuro-Oncology Fellowship Program Children's Hospital Los Angeles Associate Professor of Clinical Pediatrics Keck School of Medicine at the University of Southern California

Join to view full profile

Dr. Margol is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Margol's full profile

Already have an account?

Office
4650 Sunset Blvd
MS #54
Hollywood, CA 90027
Phone+1 323-361-8147

Education & Training

Children's Hospital of Los AngelesFellowship, Pediatric Neuro-Oncology, 2013 - 2014
Keck School of Medicine of University of Southern CaliforniaMS, Clinical, Biomedical and Translational Investigations, 2011 - 2013
Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 2010 - 2013
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Pediatrics, 2006 - 2009
Keck School of Medicine of the University of Southern CaliforniaClass of 2006

Certifications & Licensure

CA State Medical License 2008 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT Start of enrollment: 2017 Feb 22
Completed
Phase 1
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery Start of enrollment: 2018 Nov 26
Completed
Phase 2, Phase 3
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas Start of enrollment: 2019 Apr 03
Recruiting
Phase 1
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery Start of enrollment: 2019 Jul 25
Suspended
Phase 1, Phase 2
Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
Active, not recruiting
Early Phase 1
Roles: Contact
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) Start of enrollment: 2020 Dec 09
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma Start of enrollment: 2022 Feb 22
Recruiting
Not Applicable
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

3 citations
Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics.
Christopher Kuo, Dione Foon, Kaaren Waters, Clement C. Cheung, Ashley Margol
Pediatric Blood & Cancer. 2020-06-23
128 citations
Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
Jill Bayliss, Piali Mukherjee, Chao Lu, Siddhant U. Jain, Chan Chung
Science Translational Medicine. 2016-11-23
158 citations
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
Pooja Panwalkar, Jonathan Clark, Vijay Ramaswamy, Debra Hawes, Fusheng Yang
Acta Neuropathologica. 2017-07-21

Press Mentions

Children’s Hospital Los Angeles Awarded $2.5 Million Grant to Address Youth Mental Health Crisis by Training Primary Care Pediatricians in Behavioral and Mental HealthJanuary 30th, 2023